News
Exosome Diagnostics Announces that Lester Crawford, DVM, Ph.D. is joining its Scientific Advisory Board
NEW YORK, Jan. 12, 2009 – Exosome Diagnostics, Inc. today announced that Lester Crawford, DVM, Ph.D. has joined the company’s Scientific Advisory Board.
Lester M. Crawford, DVM, Ph.D., served as Deputy Commissioner, Acting Commissioner and Commissioner at the Food & Drug Administration between 2002 and 2005. This was his fourth term at FDA going back to 1975. He also served as Administrator of the Food Safety & Inspection Service at the U.S. Department of Agriculture (1987-1991). In the academic world, Crawford served for 13 years in various capacities at the University of Georgia including Chairman of the Department of Physiology and Pharmacology. At Georgetown University, he was Director of the Center for Food & Nutrition Policy from 1997-2001. And he held positions of authority at the National Food Processors Association and the Association of American Veterinary Medical Colleges in the 1990s. Crawford is a Member of the Institute of Medicine of the National Academy of Sciences and he is a Fellow of the Royal Society of Medicine in the UK. He is also a Fellow of the International Society of Food Science and Technology. He received the Award of Merit from the FDA in 1983 and the Presidential Rank Award from President Reagan in 1988 while he was at USDA. He also has been honored by the British, French and Hungarian associations. Lester Crawford is the author of over a 100 scientific publications and is the co-author of 4 books. His veterinary degree is from Auburn University (1963), his honorary doctorate is from Budapest University (1987) and he holds the Ph.D. in pharmacology from the University of Georgia (1969). At Policy Directions Inc., Dr. Crawford serves as Senior Counsel. He joined the firm in January of 2006.
About Exosome Diagnostics
Exosome Diagnostics is a developer of proprietary genetics-based diagnostic tests with applications in oncology and metabolic disease. The company’s core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers that can be reliably harvested from blood and used diagnostically for cancers and metabolic diseases. Exosome Diagnostics’ lead program is a blood-based diagnostic test for the management of brain tumor patients. For more information, visit www.exosomedx.com.
Editor’s Note: Photograph is available on request